TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

WESTMINSTER PHARMS

OncologyInfectious DiseaseMetabolic
Generics

WESTMINSTER PHARMS is a generic drug manufacturer focused on Oncology, Infectious Disease, Metabolic.

2015
Since
4
Drugs
-
Trials
62
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

LACOSAMIDE 2026-01-29
LACOSAMIDE 2026-01-21
EPLERENONE 2025-12-04
Labeling
POSACONAZOLE 2025-10-29
Manufacturing (CMC)
LACOSAMIDE 2025-10-15
Labeling
LACOSAMIDE 2025-10-15
Labeling
LACOSAMIDE 2025-10-15
Labeling
LACOSAMIDE 2025-10-15
Labeling
LACOSAMIDE 2025-10-15
Labeling
LACOSAMIDE 2025-09-03
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 42%
0 drugs Phase 3: 3 Phase 1: 2
Infectious Disease 24%
0 drugs Phase 3: 1 Phase 2: 2
Metabolic 18%
1 drugs
Dermatology 15%
0 drugs Phase 3: 1 Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Baxter specialty
Infectious Disease, Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic